** Shares of healthcare company Accolade ACCD.O more than double to $6.90 premarket
** ACCD says it has entered into an agreement where Transcarent will acquire it for $7.03 per share in cash, representing an equity value of about $621 mln
** Transaction is expected to close in Q2 2025; upon completion, ACCD will become privately held company
** Deal represents a premium of ~110% over ACCD's last closing price
** Transcarent uses generative AI to provide health information, while also providing personalized health guidance and on-demand care
** ACCD provides personalized, technology-enabled solutions to help people understand and utilize healthcare system and workplace benefits
** Deal will "create a more personalized healthcare experience for people while improving outcomes and driving down costs," ACCD says
** Up to last close, ACCD had fallen 69.5% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.